AtaiBeckley Inc. (ATAI) Form 10-Q — Aug 11, 2026
AtaiBeckley's Q2 2026 10-Q confirms the pending acquisition by Eli Lilly: each ATAI share will convert into $6.75 in cash plus one non-transferable CVR worth up to $2.50 per share tied to BPL-003 and VLS-01 development and regulatory milestones. The deal has no financing condition and is expected to close in Q3 2026, subject to stockholder approval and regulatory clearances. The quarter itself showed a wider absolute loss: net loss of $32.5 million (EPS of -$0.09) versus $27.7 million a year ago, driven by R&D spending that nearly tripled to $28.1 million following the Beckley Psytech integration, while total revenue rose to $1.7 million from $0.7 million.
Key figures
- Revenue
- $1.704 million (Q2 2026); $2.657 million (H1 2026)
- Revenue Yoy
- Q2: $1.704M vs $0.719M year-ago; H1: $2.657M vs $2.274M year-ago
- Total Assets
- 264793000
- Cash Position
- 168807000
- Shares Outstanding
- 370864669
- Ga Expense Q2
- 17771000
- Rd Expense Q2
- 28074000
- Cvr Max Per Share
- $2.50 per share tied to BPL-003 and VLS-01 milestones
- Accumulated Deficit
- $1.42 billion
- Merger Cash Per Share
- $6.75 in cash per share from Eli Lilly
- Short Term Securities
- 23041000
- Weighted Avg Shares Q2
- 360753298
- Digital Assets Bitcoin
- 5861000
- Compass Stake Market Value
- 34000000
- Compass Ads Sale Proceeds H1
- 23600000
- Pre Funded Warrant Liabilities
- 57214000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.